TIGERMED - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

HANGZHOU TIGERMED CONSULTING CO., LTD.

Hangzhou Tiger Pharmaceutical Technology Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 3347)

Overseas regulatory announcement

This announcement is made by Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (the "Company") pursuant to a Hong Kong joint transaction made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities of Hong Kong Limited.

The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.

By order of the board of directors Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

Chairman Ye Xiaoping

Hong Kong, April 28, 2026

As at the date of this announcement, the executive directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Wen Zengyu Mr.; the independent non-executive directors are Mr. Liao Qiyu, Mr. Yuan Huagang and Ms. Liu Yuwen.

Securities code: 300347 Securities abbreviation: Tigermed Announcement No. (2026) 017

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

Announcement of Resolutions of the 24th Meeting of the Fifth Board of Directors

The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that any false records, misleading statements or repeated

Joint and several liability for major omissions.

The 24th meeting of the fifth board of directors of Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company")

It will be held on April 28, 2026 in the conference room on the 6th floor, No. 508 Lujiatan Street, Binjiang District, Hangzhou. This meeting will be held on-site and via communication

Convened by a combination of voting. The meeting notice was sent to all directors by phone or email on April 14, 2026.

out. Seven directors should be present at the meeting, but actually 7 were present. This meeting was chaired by Ye Xiaoping, chairman of the company. The call for this meeting

The opening and procedures complied with the requirements of relevant laws, regulations and the company's articles of association, and the meeting was legal and valid.

After deliberation by the directors present at the meeting, the following resolutions were approved at this meeting by voting:

1. Review and adopt the “Proposal on the Company’s First Quarterly Report of 2026”;

For details, please refer to the "Company's First Quarter of 2026" disclosed at the same time on the China Securities Regulatory Commission's GEM designated information disclosure website.

Full text of the report.

Voting results: 7 votes in favor, 0 votes against, and 0 abstentions.

2. Review and adopt the “Proposal on Developing the Remuneration Management System for Directors and Senior Management Personnel”.

In order to fully implement the latest laws and regulations, further improve the company's standardized operation level, and improve the corporate governance structure

According to the "Company Law", "Guidelines on the Articles of Association of Listed Companies", "Guidelines on the Governance of Listed Companies" and other relevant laws and regulations,

In accordance with the provisions of normative documents, the company has formulated the "Remuneration Management System for Directors and Senior Management Personnel" based on its own actual conditions.

The "Remuneration Management System for Directors and Senior Management Personnel" has been reviewed and approved by the Remuneration and Assessment Committee of the Board of Directors.

Voting results: 7 votes in favor, 0 votes against, and 0 abstentions.

This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.

Announcement is hereby made.

Board of Directors of Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

April 29, 2026